poloxamer

thumb|General structurewith a = 2–130 and b = 15–67

Research

6,711 papers

A review of poloxamer 407 pharmaceutical and pharmacological characteristics.Pharmaceutical research · 2006
Poloxamer 188 as surfactant in biological formulations - An alternative for polysorbate 20/80?International journal of pharmaceutics · 2022
Poloxamer: A versatile tri-block copolymer for biomedical applications.Acta biomaterialia · 2020
Poloxamer-based in situ gelling thermoresponsive systems for ocular drug delivery applications.Drug discovery today · 2019
Purified poloxamer 188 for sickle cell vaso-occlusive crisis.The Annals of pharmacotherapy · 2004

via PubMed

Article

10 sections

Contents

Common poloxamer properties
Micellization and phase transitions
Uses
Biological effect
On multi drug resistant cancer cells
On nuclear factor kappa B
Potential degradation by sonication
References
Further reading
External links

thumb|General structurewith a = 2–130 and b = 15–67

Poloxamers are nonionic triblock copolymers composed of a central hydrophobic chain of polyoxypropylene (poly(propylene oxide)) flanked by two hydrophilic chains of polyoxyethylene (poly(ethylene oxide)). The word was coined by BASF inventor, Irving Schmolka, who received the patent for these materials in 1973. Poloxamers are also known by the trade names Pluronic, Kolliphor (pharma grade), and Synperonic.